Used as a key intermediate in the synthesis of pharmaceutical peptides, particularly in the development of protease inhibitors. Its structure allows for selective coupling in solid-phase peptide synthesis, where the Fmoc group enables controlled deprotection under mild basic conditions. The 3,4-dichlorophenyl moiety contributes to enhanced binding affinity in bioactive molecules, making it valuable in designing drugs targeting enzymes involved in metabolic and signaling pathways. Commonly employed in research settings for creating analogs with improved stability and activity.